AstraZeneca Pharma India Limited has announced a postal ballot process to seek shareholder approval for relocating its registered office from Karnataka to Maharashtra. The pharmaceutical company issued the formal notice on March 11, 2026, outlining the special business proposal and voting procedures.

Postal Ballot Timeline and Process

The company has established a comprehensive timeline for the postal ballot process, with specific dates for shareholder participation:

Shareholders whose names appear in the Register of Members or Record of Depositories as on the cut-off date of Friday, April 3, 2026, will be eligible to participate in the voting process. The company has engaged National Securities Depository Limited (NSDL) to facilitate the remote e-voting process in a secure manner.

Proposed Registered Office Relocation

The special resolution seeks approval for shifting the company's registered office from its current location in Karnataka to the State of Maharashtra. The current registered office is situated at Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bengaluru - 560045.

The proposed relocation aims to enhance administrative and operational efficiency as the company builds a stronger footprint in Mumbai, Maharashtra. This strategic move aligns with the company's commitment to transforming health outcomes for patients across India.

Regulatory Requirements and Approvals

The proposed office relocation requires multiple levels of approval in accordance with regulatory provisions:

• Shareholder Approval: Special resolution through postal ballot voting
• Central Government Approval: Through the appropriate Regional Director
• Memorandum Amendment: Alteration of the 2nd Clause of the Memorandum of Association

The resolution is being conducted pursuant to Sections 12, 13, 108, and 110 of the Companies Act, 2013, along with applicable rules and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

E-voting Process and Accessibility

The postal ballot notice is being distributed exclusively through electronic mode to shareholders whose email addresses are registered with the company or depositories. The company has provided detailed instructions for various categories of shareholders, including those holding securities in demat mode with NSDL or CDSL, and those holding physical shares.

Shareholders can access the voting platform through multiple methods, including the NSDL e-voting website at www.evoting.nsdl.com and through their respective depository participant platforms. The company has also made provisions for shareholders whose email addresses are not registered to participate in the voting process.

Documentation and Compliance

The postal ballot notice includes comprehensive explanatory statements pursuant to Section 102 of the Companies Act, 2013, detailing the material facts and reasons for the proposed resolution. The notice will be published in English and regional newspapers as required by regulatory provisions.

Mr. Vijayakrishna K.T, a Practising Company Secretary from Bengaluru, has been appointed as the Scrutinizer to conduct the postal ballot process in a fair and transparent manner. The scrutinizer will submit the results report to the Chairperson on or before Wednesday, May 13, 2026, following the completion of vote counting.

The resolution, if approved with the requisite majority, will be deemed to have been passed on the last date of the voting period, May 11, 2026, in accordance with Secretarial Standards on General Meetings issued by the Institute of Company Secretaries of India.

AstraZeneca pharma India Limited has secured a significant regulatory milestone with the Central Drugs Standard Control Organisation (CDSCO) granting permission for an expanded indication of its cancer treatment drug. The approval, received on April 9, marks an important development in the company's oncology portfolio in India.

Regulatory Approval Details

The CDSCO, under the Directorate General of Health Services, Government of India, has granted permission to AstraZeneca Pharma India Limited to import for sale and distribution of Acalabrutinib tablets 100 mg. The drug, marketed under the brand name Calquence®, has received approval for an additional therapeutic indication beyond its existing uses.

Expanded Treatment Indication

The newly approved indication allows Acalabrutinib tablets 100 mg to be used in combination therapy for treating patients with previously untreated chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). The combination therapy involves Acalabrutinib with venetoclax, with or without obinutuzumab, providing physicians with an additional treatment option for these blood cancers.

This approval specifically targets patients who have not received prior treatment for CLL/SLL, potentially expanding the patient population that can benefit from this therapeutic approach. The combination therapy represents a significant advancement in the treatment landscape for these hematological malignancies.

Market Implications

The regulatory approval paves the way for AstraZeneca Pharma India Limited to market Acalabrutinib tablets 100 mg for the specified additional indication in the Indian market. However, the company noted that marketing activities remain subject to the receipt of related statutory approvals, if any are required.

This development strengthens the company's position in India's oncology market and provides healthcare professionals with expanded treatment options for patients with CLL and SLL. The approval demonstrates the company's commitment to bringing advanced cancer treatments to Indian patients and expanding access to innovative therapies.

Compliance and Disclosure

AstraZeneca Pharma India Limited disclosed this development under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The intimation was signed by Tanya Sanish, Company Secretary & Compliance Officer, and communicated to both BSE Limited and National Stock Exchange of India Limited on April 10.